J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous Amivantamab
Question
J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous Amivantamab
Direct answer
Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 clinical study evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin. The trial focused on first-line treatment for advanced recurrent or metastatic head and neck squamous cell carcinoma. The trial achieved a 77% overall response rate among patients with non-HPV-associated disease, indicating clinical efficacy in a difficult-to-treat cancer cohort. The data was disclosed via corporate announcements on October 25, 2026. — bullish pressure on JNJ.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-26
- Published
- 2026-10-28
- Revision
- 1 · 2026-10-29
Cite as: Market Ontology, “J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous Amivantamab”, revision 1, evidence through 2026-10-26. https://marketontology.com/catalysts/2026-10-26/j-j-reports-77-response-rate-in-phase-1b-2-trial-for-subcutaneous-amivantamab-12279d
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| JNJ | ▲Bull | 1–4 weeks | Catalyst Driven | 75 |
| MRK | ▲Bull | 1–4 weeks | Catalyst Driven | 68 |
J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous Amivantamab
Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 clinical study evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin. The trial focused on first-line treatment for advanced recurrent or metastatic head and neck squamous cell carcinoma. The trial achieved a 77% overall response rate among patients with non-HPV-associated disease, indicating clinical efficacy in a difficult-to-treat cancer cohort. The data was disclosed via corporate announcements on October 25, 2026. — bullish pressure on JNJ.
Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 clinical study evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin. The trial focused on first-line treatment for advanced recurrent or metastatic head and neck squamous cell carcinoma. The trial achieved a 77% overall response rate among patients with non-HPV-associated disease, indicating clinical efficacy in a difficult-to-treat cancer cohort. The data was disclosed via corporate announcements on October 25, 2026.
- SummaryJohnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 clinical study evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin. The trial focused on first-line treatment for advanced recurrent or metastatic head and neck squamous cell carcinoma. The trial achieved a 77% overall response rate among patients with non-HPV-associated disease, indicating clinical efficacy in a difficult-to-treat cancer cohort. The data was disclosed via corporate announcements on October 25, 2026.
- JNJDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- JNJ closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- JNJ price vs. pre-event level
- JNJ volume vs. 20-day average
J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous Amivantamab
Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 clinical study evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin. The trial focused on first-line treatment for advanced recurrent or metastatic head and neck squamous cell carcinoma. The trial achieved a 77% overall response rate among patients with non-HPV-associated disease, indicating clinical efficacy in a difficult-to-treat cancer cohort. The data was disclosed via corporate announcements on October 25, 2026. — bullish pressure on MRK.
Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 clinical study evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin. The trial focused on first-line treatment for advanced recurrent or metastatic head and neck squamous cell carcinoma. The trial achieved a 77% overall response rate among patients with non-HPV-associated disease, indicating clinical efficacy in a difficult-to-treat cancer cohort. The data was disclosed via corporate announcements on October 25, 2026.
- SummaryJohnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 clinical study evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin. The trial focused on first-line treatment for advanced recurrent or metastatic head and neck squamous cell carcinoma. The trial achieved a 77% overall response rate among patients with non-HPV-associated disease, indicating clinical efficacy in a difficult-to-treat cancer cohort. The data was disclosed via corporate announcements on October 25, 2026.
- MRKDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- MRK closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- MRK price vs. pre-event level
- MRK volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| JNJ | Bullish | 266.30 2026-10-26 | Pending | Pending | Pending |
| MRK | Bullishagreed | 140.61 2026-10-26 | +0.86% | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-27Bristol Myers reports positive Phase 3 data on iza-brenBMY JNJ
- 2026-10-26Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck StudyJNJ
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ
- 2026-10-26Microbiotica presents Phase 1b melanoma data combining MB097 with KeytrudaMRK+0.86%
- 2026-10-26Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancerJNJ MRK+0.86%
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ MRK+0.86%
- 2026-10-26Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck StudyJNJ
- 2026-10-26Microbiotica presents Phase 1b melanoma data combining MB097 with KeytrudaMRK+0.86%
Find trades for this development
Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.
First 10 runs free
See today's live cards
Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.